Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ticagrelor

ticagrelor

18 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ticagrelor

57 trials tracked of ticagrelor: 41 in phase 3 or 4 and 18 with published results. The most-cited published study has 683 citations.

57Trials tracked
41Phase 3 & 4
0Recruiting
18With published results
Phase distribution
Phase 4 31 Phase 3 10 Phase 2 10 Phase 1 4 Other / NA 2
  1. Phase 3 Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Completed · 683 cited
  2. Phase 4 Tailored Antiplatelet Therapy Following PCI Completed · 421 cited
  3. Phase 4 Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery Completed · 242 cited
  4. Phase 3 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] Completed · 109 cited
  5. Phase 3 THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death Completed · 105 cited
  6. Phase 3 A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention Completed · 76 cited
Show 44 more trials
  1. Phase 4 Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease Completed · 59 cited
  2. Phase 3 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation Completed · 50 cited
  3. Phase 4 The Effect of IV Cangrelor and Oral Ticagrelor Study Completed · 46 cited
  4. Phase 4 Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine Completed · 36 cited
  5. Phase 4 A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function: Completed · 28 cited
  6. Phase 4 Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor Completed · 22 cited
  7. Phase 3 A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease Completed · 17 cited
  8. Phase 3 Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes Completed · 14 cited
  9. Phase 4 Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Completed · 10 cited
  10. Phase 4 Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis Completed · 9 cited
  11. Phase 4 Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease Completed · 8 cited
  12. Phase 4 Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention Completed · 8 cited
  13. Phase 4 Brilinta DaYu Study Completed
  14. Phase 4 Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI Completed
  15. Phase 4 Clopidogrel Versus Ticagrelor in Type-2 Diabetes Completed
  16. Phase 4 Antiplatelet Therapy After Cardiac Arrest Completed
  17. Phase 4 P3AMI Antiplatelet Trial Completed
  18. Phase 4 Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study Completed
  19. Phase 4 Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction Completed
  20. Phase 4 Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI Completed
  21. Phase 4 NIRS Ticagrelor Evaluation Completed
  22. Phase 4 Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis Completed
  23. Phase 4 Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR) Completed
  24. Phase 4 Chewed Versus Integral Pill of Ticagrelor Completed
  25. Phase 4 CES1 Crossover Trial of Clopidogrel and Ticagrelor Completed
  26. Phase 4 The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin Completed
  27. Phase 4 Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction Completed
  28. Phase 4 A Pharmacodynamic Study With Ticagrelor in Hispanic Patients Completed
  29. Phase 4 A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS Completed
  30. Phase 4 A Pharmacodynamic Study With Ticagrelor in African American Patients Completed
  31. Phase 4 A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI) Completed
  32. Phase 4 Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients Completed
  33. Phase 3 Efficacy and Safety of Low-dose Ticagrelor Completed
  34. Phase 3 Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) Completed
  35. Phase 3 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome Completed
  36. Phase 2 Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis Completed
  37. Phase 2 Cangrelor Ticagrelor Transition Study Completed
  38. Phase 2 Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion Completed
  39. Phase 2 A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome Completed
  40. Phase 2 A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants Completed
  41. Phase 2 Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study Completed
  42. Phase 2 A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease Completed
  43. Phase 2 An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease Completed
  44. Phase 2 A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders Completed

Showing the 50 most-cited and recently-updated of 57 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Low Dose Ticagrelor and Aspirin Reduce Early Neurological Deterioration in Ischemic Stroke
Neurology RCT
Low Dose Ticagrelor and Aspirin Reduce Early Neurological Deterioration in Ischemic Stroke Trial shows ticagrelor and aspirin may reduce neurological decline
A randomized trial suggests that low-dose ticagrelor combined with aspirin significantly reduces early neurological deterioration in high-ri…
A new clinical trial suggests that a specific combination of ticagrelor and aspirin may help prevent early neurological decline after a stro…
Sep 10, 2026
Bayesian analysis of P2Y12 inhibitors identifies clinical uncertainties and equivalence in acute coronary syndromes
Cardiology Meta-analysis
Bayesian analysis of P2Y12 inhibitors identifies clinical uncertainties and equivalence in acute coronary syndromes Trial Shows Prasugrel May Offer Benefits Over Clopidogrel for Heart Patients
This meta-analysis of 60,619 patients following percutaneous coronary intervention evaluates P2Y12 inhibitors using a Bayesian framework. Th…
A large analysis of over 60,000 patients suggests prasugrel may be more effective than clopidogrel for preventing major heart events after p…
medRxiv Sep 7, 2026
Impact of Percutaneous Coronary Intervention Complexity on Ticagrelor or Prasugrel Monotherapy Efficacy
Cardiology RCT
Impact of Percutaneous Coronary Intervention Complexity on Ticagrelor or Prasugrel Monotherapy Efficacy Complex heart procedures do not change risks of certain medications
A post hoc analysis of the NEO-MINDSET trial evaluates if PCI complexity influences the safety and efficacy of potent P2Y inhibitor monother…
New analysis shows that complex heart procedures do not change the safety or effectiveness of specific blood-thinning medications.
Sep 2, 2026
Ticagrelor monotherapy following primary PCI for STEMI shows reduced non-access site bleeding
Cardiology RCT
Ticagrelor monotherapy following primary PCI for STEMI shows reduced non-access site bleeding Trial shows ticagrelor monotherapy may reduce bleeding after heart attack
This pilot study compared ticagrelor monotherapy against ticagrelor plus aspirin in patients with STEMI after primary PCI. The trial reporte…
A pilot study suggests that using ticagrelor alone after a heart attack may reduce specific types of bleeding compared to a dual-drug approa…
Sep 2, 2026
Clopidogrel plus aspirin for 21 days provides favorable net clinical benefit in minor ischemic stroke
Neurology Sys. Review
Clopidogrel plus aspirin for 21 days provides favorable net clinical benefit in minor ischemic stroke Dual antiplatelet therapy shows mixed results for stroke prevention
This Bayesian network meta-analysis of 8 trials involving 50,349 adults with minor ischemic stroke or high-risk TIA found that clopidogrel p…
New data compares different blood thinner combinations to find the best way to prevent a second stroke after a minor medical emergency.
Sep 1, 2026
Ticagrelor monotherapy after primary PCI shows 3.1% MACCE versus 2.0% in DAPT group
Cardiology RCT
Ticagrelor monotherapy after primary PCI shows 3.1% MACCE versus 2.0% in DAPT group Trial shows ticagrelor alone may reduce bleeding after heart attack
This pilot randomized controlled trial of 200 STEMI patients compared ticagrelor monotherapy to ticagrelor plus aspirin (DAPT) after primary…
A new trial looks at whether using one blood thinner instead of two can reduce bleeding risks for patients after a heart attack.
Sep 1, 2026
Noninferiority of Ultra-thin Biodegradable Polymer Sirolimus Eluting Stents in Diabetic Patients
Cardiology RCT
Noninferiority of Ultra-thin Biodegradable Polymer Sirolimus Eluting Stents in Diabetic Patients New stent type shows promise for patients with diabetes and heart disease
A multicenter trial confirms that ultra-thin biodegradable polymer sirolimus-eluting stents meet noninferiority goals compared to durable po…
A new ultra-thin stent may offer a reliable option for people with both diabetes and complex heart disease.
Aug 27, 2026
Ticagrelor and prasugrel show no statistically credible difference in 1-year MACE for ACS patients
Cardiology Meta-analysis
Ticagrelor and prasugrel show no statistically credible difference in 1-year MACE for ACS patients Comparing Ticagrelor and Prasugrel for Patients with Heart Conditions After Surgery
This meta-analysis of retrospective new-user cohort studies analyzed 133,718 adults with acute coronary syndrome undergoing first PCI. The s…
A large study compared two heart medications to see which was safer and more effective for patients after a heart procedure.
medRxiv Aug 17, 2026
Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patients
Cardiology Meta-analysis
Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patients Ticagrelor Shows Lower Mortality Risk Than Clopidogrel for Heart Patients
This meta-analysis of 31,729 adult STEMI patients post-PCI found that ticagrelor significantly reduced all-cause mortality (OR = 0.64) and m…
A large analysis of over 31,000 patients suggests ticagrelor may lower mortality and heart attack risks compared to clopidogrel after a hear…
NEJM Jul 26, 2026
Early dual antiplatelet therapy improves outcomes after ischaemic stroke thrombolysis
Neurology RCT
Early dual antiplatelet therapy improves outcomes after ischaemic stroke thrombolysis Stroke Patients Gain Better Recovery With Early Double Blood Thinner Combo
A Chinese trial found that starting aspirin and ticagrelor within six hours after thrombolysis boosted excellent functional outcomes at 90 d…
Adding a second blood thinner within hours helps more stroke patients regain full function without raising bleeding risks
May 15, 2026
FDA approves ticagrelor for multiple indications in cardiology and neurology
Cardiology FDA Approval
FDA approves ticagrelor for multiple indications in cardiology and neurology Brilinta Now Approved for Stroke Prevention in Three Key Groups
The FDA approved ticagrelor (Brilinta) for patients with ACS, CAD at high risk, and acute ischemic stroke or high-risk TIA. In ACS, it was s…
A widely used heart medication now has FDA approval to prevent first strokes in people with diabetes and to protect against repeat strokes a…
FDA May 14, 2026
Tailored antiplatelet strategy showed no benefit over standard dual therapy in high-risk PCI patients
Cardiology RCT
Tailored antiplatelet strategy showed no benefit over standard dual therapy in high-risk PCI patients New heart drug plan failed to beat standard care for high-risk patients
This randomized clinical trial compared a tailored antiplatelet strategy involving early low-dose ticagrelor followed by late de-escalation …
Doctors tested a custom heart drug plan but found standard treatment still works best for high-risk patients
May 5, 2026

All ticagrelor Articles